Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of VX-659 in Healthy Subjects and Subjects With Cystic Fibrosis
NCT03029455Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bamocaftor in cystic fibrosis (CF) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of subjects with adverse events (AEs) and serious adverse events (SAEs) at Day 50. Started Nov 2016; status: completed.
02
Drugs
bamocaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03029455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03029455.